CR Sanjiu(000999) 证券日报网·2025-03-28 12:45Core Viewpoint - The launch of 999 Yiqi Qingfei Granules by China Resources Sanjiu marks a significant advancement in the treatment of respiratory infection recovery symptoms, filling a market gap for rehabilitation medications [1][2]. Group 1: Product Launch and Significance - China Resources Sanjiu officially released its first traditional Chinese medicine class 3.2 new drug, 999 Yiqi Qingfei Granules, at the First Traditional Chinese Medicine Industry Interconnectivity Conference [1]. - The drug is developed in collaboration with academician Zhang Boli and is the first to be approved by the National Medical Products Administration specifically for treating symptoms during the recovery phase of respiratory infections [1][2]. - The launch signifies an expansion of China Resources Sanjiu's product offerings in the respiratory category, aiming to address the rehabilitation issues often overlooked in respiratory infections [1][2]. Group 2: Development and Composition - The formulation of 999 Yiqi Qingfei Granules is based on classic prescriptions such as Shengmai San and Pingwei San, adjusted according to clinical rehabilitation experiences [2]. - The granules focus on enhancing energy and nourishing yin, improving symptoms like fatigue, shortness of breath, and dry cough with little phlegm during the recovery phase of respiratory infections [2]. Group 3: Strategic Vision - The company aims to leverage traditional Chinese medicine values through innovative research, providing safe and effective treatment options for consumers suffering from prolonged cold symptoms [2]. - The product is part of a broader "1+N" brand strategy that encompasses full-cycle management of common household diseases, indicating a comprehensive approach to health care [2]. - 999 Yiqi Qingfei Granules is positioned as a key product in the company's respiratory category, highlighting its strategic importance for future growth [2].